Skip to main content

Table 1 Pharmacokinetic parameters for prednisolone after oral and intramuscular administration during growth-promoting and therapeutic treatment

From: Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration

  Oral treatment Intramuscular treatment
  40 mg day−1 0.5 mg kg−1 day−1 40 mg day−1 0.5 mg kg−1 day−1
Cmax (μg L−1) 2.96 ± 1.50 7.01 ± 1.52 117 ± 25.8 156 ± 78.1
Tmax (h) 2.95 ± 0.820 3.85 ± 0.909 0.168 ± 0.063 0.866 ± 0.273
AUC0-tinf (h μg L−1) 26.1 ± 19.1 75.5 ± 25.0 232 ± 17.5 678 ± 11.5
ka (h−1) 0.363 ± 0.099 0.307 ± 0.129 17.1 ± 11.2 1.93 ± 0.395
T1/2a (h) 2.05 ± 0.588 2.53 ± 0.854 0.064 ± 0.052 0.370 ± 0.083
kel (h−1) 0.362 ± 0.091 0.245 ± 0.053 0.325 ± 0.046 0.132 ± 0.092
T1/2el (h) 2.04 ± 0.553 2.97 ± 0.728 2.16 ± 0.308 3.80 ± 0.499
Vd/F (L kg−1) 11.9 ± 4.89 30.1 ± 9.98 0.503 ± 0.215 2.47 ± 1.61
Cl/F (L h−1 kg−1) 4.66 ± 2.68 7.15 ± 1.97 0.346 ± 0.026 0.737 ± 0.012
  1. Average parameter values and SD were determined on the basis of 12 samples. Therapeutic treatment concerned the administration of 0.5 mg prednisolone kg−1 day−1, whereas during growth-promoting treatment 40 mg day−1 was administered